Abstract
Tamoxifen is a selective estrogen receptor modulator (SERM) used for the treatment and prevention of breast cancer. Tamoxifen has been reported to protect against the progression of coronary artery diseases in human and different atherosclerosis animal models by blocking the appearance of the atheromatous plaque. However, the molecular mechanism of this effect remains unknown. Acyl-CoA:cholesterol acyl transferase (ACAT) catalyzes the biosynthesis of cholesteryl esters, which are the major lipids found in the atheromatous plaque. In this paper we have tested whether ACAT might be inhibited by tamoxifen. We show, using molecular modeling, that tamoxifen displays three-dimensional structural homology with Sah 58-035 (3-[decyldimethylsilyl]-N-[2-(4-methylphenyl)-1-phenylethyl]-propanamide), a prototypical inhibitor of ACAT. We report that tamoxifen inhibits ACAT in a concentration-dependent manner on rat liver microsomal extract. We show that the presence on estrogen receptor ligands of a backbone isosteric to the diphenyl ethane backbone of Sah 58-035 constitutes a pharmacophore for ACAT inhibition. More importantly, tamoxifen was able to inhibit ACAT on intact macrophages stimulated with acetylated low-density lipoproteins and blocked the formation of foam cells, a step that precedes the formation of the atheromatous plaque. This work constitutes the first evidence that tamoxifen is an inhibitor of ACAT and foam cell formation at therapeutic doses and that this may account for its atheroprotective action.
Footnotes
-
This work was supported by the Institut National de la Recherche Médicale, a grant from the Association pour la Recherche sur le Cancer (ARC 5648), and a grant from the Caisse d'Assurance Maladie des Profession Libérales Provinces (Paris) and Affichem. P.D.M. was supported by the Ministère de la Recherche et de la Technologie.
-
DOI: 10.1124/jpet.103.060426.
-
ABBREVIATIONS: ACAT, acyl-CoA:cholesterol acyl transferase; ER, estrogen receptor; DPE, diphenylethane; DPM, diphenylmethane; RPM, rat peritoneal macrophage; LDL, low-density lipoprotein; AcLDL, acetylated low-density lipoprotein; Sah 58-035, 3-[decyldimethylsilyl]-N-[2-(4-methylphenyl)-1-phenylethyl]-propanamide; RU 39,411, 11β-[4-N,N-[diethylaminoethoxy]phenyl]-estra-1,3,5(10)-triene-3,17β-diol; RU 58,668, 11β-[[[(4,4,5,5,5,-pentafluoropentyl)sulfonyl]pentyloxy]phenyl]-estra-1,3,5(10)-triene-3,17β-diol; PBPE, 1-[2-(4-benzyl-phenoxy)-ethyl]-N-pyrrolidine hydrochloride; DMBPE, [2-(4-benzyl-phenoxy)-ethyl]-N,N-dimethyl-amine hydrochloride; TLC, thin-layer chromatography; ICI 182,780, Faslodex (fulvestrant); DMEM, Dulbecco's modified Eagle's medium; CI-628, nitromiphene citrate [α-(4-N-pyrrolidinethoxyl)phenyl-4-methoxy-α-nitrostilbene]); ICI 164,384, (N-n-butyl-N-methyl-11-[3,17β-di-hydroxyestra-1,3,5(10)-trien-7α-yl]-undecanamide.
- Received September 24, 2003.
- Accepted November 12, 2003.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|